Cargando…
VEGF, VEGFR2 and GSTM1 polymorphisms in outcome of multiple myeloma patients treated with thalidomide-based regimens
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520405/ https://www.ncbi.nlm.nih.gov/pubmed/28665417 http://dx.doi.org/10.1038/bcj.2017.58 |
| _version_ | 1783251814092636160 |
|---|---|
| author | Lopes-Aguiar, L Delamain, M T Brito, A B C Lourenço, G J Costa, E F D Oliveira, G B Vassallo, J De Souza, C A Lima, C S P |
| author_facet | Lopes-Aguiar, L Delamain, M T Brito, A B C Lourenço, G J Costa, E F D Oliveira, G B Vassallo, J De Souza, C A Lima, C S P |
| author_sort | Lopes-Aguiar, L |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-5520405 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2017 |
| publisher | Nature Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-55204052017-07-26 VEGF, VEGFR2 and GSTM1 polymorphisms in outcome of multiple myeloma patients treated with thalidomide-based regimens Lopes-Aguiar, L Delamain, M T Brito, A B C Lourenço, G J Costa, E F D Oliveira, G B Vassallo, J De Souza, C A Lima, C S P Blood Cancer J Letter to the Editor Nature Publishing Group 2017-06 2017-06-30 /pmc/articles/PMC5520405/ /pubmed/28665417 http://dx.doi.org/10.1038/bcj.2017.58 Text en Copyright © 2017 The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ |
| spellingShingle | Letter to the Editor Lopes-Aguiar, L Delamain, M T Brito, A B C Lourenço, G J Costa, E F D Oliveira, G B Vassallo, J De Souza, C A Lima, C S P VEGF, VEGFR2 and GSTM1 polymorphisms in outcome of multiple myeloma patients treated with thalidomide-based regimens |
| title | VEGF, VEGFR2 and GSTM1 polymorphisms in outcome of multiple myeloma patients treated with thalidomide-based regimens |
| title_full | VEGF, VEGFR2 and GSTM1 polymorphisms in outcome of multiple myeloma patients treated with thalidomide-based regimens |
| title_fullStr | VEGF, VEGFR2 and GSTM1 polymorphisms in outcome of multiple myeloma patients treated with thalidomide-based regimens |
| title_full_unstemmed | VEGF, VEGFR2 and GSTM1 polymorphisms in outcome of multiple myeloma patients treated with thalidomide-based regimens |
| title_short | VEGF, VEGFR2 and GSTM1 polymorphisms in outcome of multiple myeloma patients treated with thalidomide-based regimens |
| title_sort | vegf, vegfr2 and gstm1 polymorphisms in outcome of multiple myeloma patients treated with thalidomide-based regimens |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520405/ https://www.ncbi.nlm.nih.gov/pubmed/28665417 http://dx.doi.org/10.1038/bcj.2017.58 |
| work_keys_str_mv | AT lopesaguiarl vegfvegfr2andgstm1polymorphismsinoutcomeofmultiplemyelomapatientstreatedwiththalidomidebasedregimens AT delamainmt vegfvegfr2andgstm1polymorphismsinoutcomeofmultiplemyelomapatientstreatedwiththalidomidebasedregimens AT britoabc vegfvegfr2andgstm1polymorphismsinoutcomeofmultiplemyelomapatientstreatedwiththalidomidebasedregimens AT lourencogj vegfvegfr2andgstm1polymorphismsinoutcomeofmultiplemyelomapatientstreatedwiththalidomidebasedregimens AT costaefd vegfvegfr2andgstm1polymorphismsinoutcomeofmultiplemyelomapatientstreatedwiththalidomidebasedregimens AT oliveiragb vegfvegfr2andgstm1polymorphismsinoutcomeofmultiplemyelomapatientstreatedwiththalidomidebasedregimens AT vassalloj vegfvegfr2andgstm1polymorphismsinoutcomeofmultiplemyelomapatientstreatedwiththalidomidebasedregimens AT desouzaca vegfvegfr2andgstm1polymorphismsinoutcomeofmultiplemyelomapatientstreatedwiththalidomidebasedregimens AT limacsp vegfvegfr2andgstm1polymorphismsinoutcomeofmultiplemyelomapatientstreatedwiththalidomidebasedregimens |